We use cookies to help provide you with the best possible online experience. By using this site, you agree that we may store and access cookies on your device. You can find out more about how to set your own preferences here.
Accept cookies

Successful launch of Cerbios’ products in Pakistan

Lugano / Barbengo, May 04 2014

After Korea and Japan the request for Cerbios’ products has increased also in other Asian territories, where customers appreciate the high quality standard of Cerbios production site in Switzerland.

In fact, even in territories where low cost products are dominating the market, there is an increasing demand for value Pharmaceuticals providing consistently and in a reliable way, high quality products.

In Pakistan Cerbios is collaborating with RG Pharmaceutica, a fast growing organization dedicated to provide exemplary patient’s care.

Cerbios supplies its (6S)-5-MeTHF Calcium Salt for nutritional use in Pakistan exclusively to RG Pharmaceutica who commercializes the respective Nutraceutical specialties MyfolTM & MetafolTM exclusively based on Cerbios’ active ingredient.

“After the successful launch of MyfolTM and MetafolTM during 2013,  we are pleased to announce the upcoming launch of NewfloraTM in Pakistan” says Gabriel Haering, CEO. “We are confident that the exclusive distribution rights granted also for this product to RG Pharmaceutica will allow our partner in Pakistan to further invest in its organization dedicated to market and distribute high quality products in this territory”.

NewfloraTM is based on Cerbios’ Enterococcus faecium SF68®, a probiotic active ingredient of pharmaceutical quality for the prevention and treatment of intestinal disorders. It balances the intestinal ecosystem and acts against diarrhea.

In Switzerland Cerbios’ Enterococcus faecium SF68® was registered as pharmaceutical probiotic in 1979 and commercialized under the trade name Bioflorin. In the 80’s  it quickly took over the market lead and is today still No 1 in class A7F.

It is used in clinical conditions in which changes in the intestinal flora and, as their consequence, any disorder of the intestinal balance play a decisive role, such as 

  • Enteritis, enterocolitis of adults
  • Enteritis, enterocolitis of children
  • Dyspepsia due to dietary changes of infants
  • Dysbacteria in intestinal tract of various origin, such as after antibiotic therapy or disorders due to dietary and diet-related changes
  • Traveller’s diarrhoea 
About Cerbios-Pharma SA

Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide.

Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAIs and by the Biological Division for monoclonal antibodies, recombinant proteins and pharma probiotics.

Cerbios provides full CMC support to its world-wide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
[[ getItemTitle(currentIndex) ]]